Phathom Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Phathom Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's primary asset is vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Phathom markets vonoprazan in the United States under the brand name VOQUEZNA. VOQUEZNA is approved for multiple indications, including the relief of heartburn associated with Non-Erosive GERD, the healing and maintenance of healing of Erosive GERD, and in combination with antibiotics (VOQUEZNA TRIPLE PAK and DUAL PAK) for the treatment of Helicobacter pylori infection in adults.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding and optimizing the direct sales force to deepen engagement with high-prescribing gastroenterologists (GIs) and primary care physicians in the U.S. market.
Expected impact: Aims to capture 20% to 30% market share of the gastroenterology PPI prescription market, driving the company toward its long-term goal of $1 billion in annual gastroenterology prescription revenue.
Deploying national omnichannel DTC advertising campaigns, such as 'VOQUEZNA Can Kick Some Acid' and 'GERD Is No Joke' featuring Kenan Thompson, to raise consumer brand awareness and encourage patient-physician dialogue.
Expected impact: Accelerates patient adoption, drives prescription requests, and establishes VOQUEZNA as a superior alternative to legacy proton pump inhibitors (PPIs).
Conducting the Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA 20 mg once daily in adults with endoscopically-confirmed EoE and dysphagia.
Expected impact: Positions VOQUEZNA as a potential first-line, pre-biologic treatment option for EoE, expanding the drug's therapeutic reach and commercial potential.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Phathom in-licensed the exclusive development and commercialization rights to vonoprazan in the United States, Europe, and Canada from Takeda in May 2019, which forms the entire foundation of Phathom's product portfolio.
Terms: Takeda received upfront cash and equity, and is eligible to receive future cash milestones of up to $250 million plus royalties on net sales of vonoprazan-based products.
Provides non-dilutive debt financing to fund the commercial launch of VOQUEZNA and ongoing clinical development programs.
Terms: Originally a $200 million facility, expanded to $300 million in December 2023. In February 2026, the agreement was modified to reduce the outstanding principal to $175 million, lower the interest rate, and extend the maturity date to February 2029.